Cardiovascular and metabolic diseases are the major causes of morbidity and mortality in the Western Countries. Metabolic syndrome (defined as 3 out of 5 factors among increased waist circumference, hypertension, high blood glucose, high triglyceride and low high density lipoprotein (HDL) cholesterol concentrations) is associated with increased cardiometabolic risk. Other indexes have been proposed and validated, based on the measurement of plasma concentration of lipids, glucose and liver enzymes. In the SEMEOTICONS project we plan to measure parameters related to increased cardiometabolic risk, e.g. skin accumulation of cholesterol and advanced glycated end products, liver enzyme alteration by changing in skin and eye color and obesity. The results will allow to evaluate cardiometabolic risk using non invasive clinical parameters. The new score obtained will be compared with previously validated indexes. In this paper we have evaluated the most common cardiometabolic risk scores i.e., VAI (Visceral Adiposity Index), HTG- Waist (Hypertriglyceridemic Waist), FLI (Fatty Liver Index) and LAP (Lipid Accumulation Product), that we will use during the project. Copyright © 2014 SCITEPRESS - Science and Technology Publications. All rights reserved.
Evaluation of published clinical scores for the prediction of cardiometabolic risk in the SEMEOTICONS project
Gaggini Melania;Buzzigoli Emma;Ciociaro Demetrio;Coppini Giuseppe;Marraccini Paolo;Gastaldelli Amalia
2014
Abstract
Cardiovascular and metabolic diseases are the major causes of morbidity and mortality in the Western Countries. Metabolic syndrome (defined as 3 out of 5 factors among increased waist circumference, hypertension, high blood glucose, high triglyceride and low high density lipoprotein (HDL) cholesterol concentrations) is associated with increased cardiometabolic risk. Other indexes have been proposed and validated, based on the measurement of plasma concentration of lipids, glucose and liver enzymes. In the SEMEOTICONS project we plan to measure parameters related to increased cardiometabolic risk, e.g. skin accumulation of cholesterol and advanced glycated end products, liver enzyme alteration by changing in skin and eye color and obesity. The results will allow to evaluate cardiometabolic risk using non invasive clinical parameters. The new score obtained will be compared with previously validated indexes. In this paper we have evaluated the most common cardiometabolic risk scores i.e., VAI (Visceral Adiposity Index), HTG- Waist (Hypertriglyceridemic Waist), FLI (Fatty Liver Index) and LAP (Lipid Accumulation Product), that we will use during the project. Copyright © 2014 SCITEPRESS - Science and Technology Publications. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
prod_315990-doc_92126.pdf
solo utenti autorizzati
Descrizione: Evaluation of Published Clinical Scores for the Prediction of Cardiometabolic Risk in the SEMEOTICONS project
Tipologia:
Versione Editoriale (PDF)
Dimensione
712.04 kB
Formato
Adobe PDF
|
712.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.